Product/Composition:- | Palbociclib Tablet |
---|---|
Strength:- | 75 mg, 100mg, 125 mg |
Form:- | Oral Tablets |
Reference Brands:- | Ibrance® (US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Palbociclib Tablets (brand name Ibrance®) are used to treat HR+ HER2-negative breast cancer. As a CDK 4/6 inhibitor, it halts cancer cell division. Available in 125 mg, 100 mg, and 75 mg strengths, Palbociclib is used in combination with letrozole or fulvestrant for advanced or metastatic cases. Manufactured under GMP standards, it is a trusted oncology treatment for US and EU markets.
Palbociclib Tablets are a CDK 4/6 inhibitor used for the treatment of hormone receptor-positive (HR+), HER2-negative breast cancer. It works by blocking the proteins responsible for cancer cell division, halting cell cycle progression. Marketed under the brand name Ibrance®, Palbociclib is typically used in combination with letrozole or fulvestrant for the treatment of advanced or metastatic breast cancer. Available in 125 mg, 100 mg, and 75 mg tablet strengths, Palbociclib is manufactured in GMP-compliant facilities, making it a reliable and effective solution for oncology treatment in both US and EU markets.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications